Potential prostate cancer treatment targets genetic mutations

Research has found that the gene-targeting drug Lynparza® (olaparib), currently used to treat breast and ovarian cancer, could also be used to treat prostate cancer. This could make it the first drug for prostate cancer that exploits genetic mutations.  A new clinical trial from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust (both London, UK) has found that the drug olaparib, already licensed for use in treating breast and ovarian cancers, could also be used to treat prostate cancer. Results from the TOPARP-B trial, published in The Lancet Oncology, revealed that 80% of men with prostate...